Pharmacodynamic and Pharmacokinetic Studies on Prizidilol and Nipradilol (K-351), Antihypertensive Drugs with Combined Vasodilator and β-Adrenoceptor Blocking Actions, in Rabbits

Open Access
Publisher Website
Google Scholar
Abstract
Effects of prizidilol and nipradilol (K-351), .beta.-adrenoceptor antagonists with vasodilator action, on blood pressure and heart rate were studied in normotensive conscious rabbits after i.v. administration. In addition, relationships between plasma drug concentrations and .beta.-adrenoceptor blocking activity were investigated; they were estimated by the inhibition of isoproterenol-induced tachycardia and vasodilator activity, as assessed by the inhibition of pressor response to angiotensin II (ANG II). Prizidilol (4 mg/kg) produced a significant and sustained fall in blood pressure and a slight increase in heart rate, while hydralazine (2 mg/kg) caused the same degree of hypotension and a marked tachycardia. Nipradilol (1 mg/kg) caused a significant reduction of resting heart rate, but had no significant effect on blood pressure. Propranolol (1 mg/kg) did not affect resting blood pressure and heart rate. Hypertensive response to ANG II was significantly attenuated only by hydralazine. Isoproterenol-induced tachycardia was significantly suppressed by prizidilol, nipradilol and propranolol. Good correlations were observed between .beta.-adrenoceptor blocking activity and plasma drug concentrations. These data suggest that prizidilol has an advantage over hydralazine by inducing less tachycardia, but it still may cause a certain degree of increase in heart rate. Nipradilol has a more potent .beta.-adrenoceptor blocking action than propranolol, while its vasodilator action is not obvious, at least not in rabbits. Plasma concentrations of prizidilol and nipradilol are good indicators for .beta.-adrenoceptor blocking activity, but not for vasodilator activity.

This publication has 16 references indexed in Scilit: